PX 20350 - FXR agonist Cpd 22 |
Catalog No.GB40336 |
Potent farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FXR direct reporter (DR) assay (6 nM vs 30 nM for GW 4064). Cpd 22 showed a linear dose-dependent reduction in total plasma triglycerides and total plasma cholesterol.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1198085-23-2
Sample solution is provided at 25 µL, 10mM.
Potent farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FXR direct reporter (DR) assay (6 nM vs 30 nM for GW 4064). Cpd 22 showed a linear dose-dependent reduction in total plasma triglycerides and total plasma cholesterol.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *